

# THROMBOSIS ADVISER

## Approved antiplatelets for the secondary prevention of ACS

Drug	Target	Dose/regimen	Supporting data
Acetylsalicylic acid	Irreversibly inhibits the COX1 enzyme	75–325 mg daily	Meta-analysis of 195 clinical trials <sup>228</sup>
Thienopyridine	Irreversibly binds to the ADP receptor P2Y <sub>12</sub>	Clopidogrel: 75 mg daily Prasugrel: 10 mg daily	CURE (clopidogrel + ASA) <sup>229</sup>  TRITON-TIMI 38 (prasugrel + ASA) <sup>232</sup>  TRILOGY ACS (prasugrel vs clopidogrel) <sup>244</sup>
Ticagrelor	Non-thienopyridine: reversibly binds to P2Y <sub>12</sub> , noncompetitively with ADP	90 mg twice daily	PLATO (ticagrelor + ASA) <sup>231</sup>

ACS, acute coronary syndrome; ADP, adenosine diphosphate; COX1, cyclooxygenase-1.